Avanos Medical (AVNS)
Market Price (2/15/2026): $14.91 | Market Cap: $691.8 MilSector: Health Care | Industry: Health Care Supplies
Avanos Medical (AVNS)
Market Price (2/15/2026): $14.91Market Cap: $691.8 MilSector: Health CareIndustry: Health Care Supplies
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11% | Weak multi-year price returns2Y Excs Rtn is -58%, 3Y Excs Rtn is -118% | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -72% |
| Attractive yieldFCF Yield is 11% | Key risksAVNS key risks include [1] persistent and widening losses driven by a lack of revenue and earnings growth, Show more. | |
| Low stock price volatilityVol 12M is 38% | ||
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, and Targeted Therapies. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Attractive yieldFCF Yield is 11% |
| Low stock price volatilityVol 12M is 38% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, and Targeted Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -58%, 3Y Excs Rtn is -118% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -72% |
| Key risksAVNS key risks include [1] persistent and widening losses driven by a lack of revenue and earnings growth, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Avanos Medical (AVNS) stock has gained about 35% since 10/31/2025 because of the following key factors:
1. Strong Third Quarter 2025 Financial Performance and Upgraded Full-Year Guidance. Avanos Medical reported robust third-quarter 2025 earnings on November 5, 2025, exceeding analyst expectations with an adjusted earnings per share of $0.22 against a forecast of $0.18, and revenues of $178 million compared to an anticipated $167.5 million. Concurrently, the company raised and narrowed its 2025 estimated revenue guidance to between $690 million and $700 million and its adjusted diluted earnings per share guidance to a new range of $0.85 to $0.95, signaling improved financial outlook and operational efficiency.
2. Strategic Co-marketing Agreement with Siemens Healthineers. In January 2026, Avanos Medical announced a significant strategic co-marketing agreement with Siemens Healthineers. This collaboration focuses on integrating Avanos' radiofrequency ablation technologies with Siemens Healthineers' imaging systems to advance solutions for outpatient and interventional pain care, potentially expanding market reach and adoption of Avanos' pain management products.
Show more
1. Strong Third Quarter 2025 Financial Performance and Upgraded Full-Year Guidance. Avanos Medical reported robust third-quarter 2025 earnings on November 5, 2025, exceeding analyst expectations with an adjusted earnings per share of $0.22 against a forecast of $0.18, and revenues of $178 million compared to an anticipated $167.5 million. Concurrently, the company raised and narrowed its 2025 estimated revenue guidance to between $690 million and $700 million and its adjusted diluted earnings per share guidance to a new range of $0.85 to $0.95, signaling improved financial outlook and operational efficiency.
2. Strategic Co-marketing Agreement with Siemens Healthineers. In January 2026, Avanos Medical announced a significant strategic co-marketing agreement with Siemens Healthineers. This collaboration focuses on integrating Avanos' radiofrequency ablation technologies with Siemens Healthineers' imaging systems to advance solutions for outpatient and interventional pain care, potentially expanding market reach and adoption of Avanos' pain management products.
Show more
Stock Movement Drivers
Fundamental Drivers
The 34.2% change in AVNS stock from 10/31/2025 to 2/15/2026 was primarily driven by a 33.1% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.11 | 14.91 | 34.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 692 | 700 | 1.1% |
| P/S Multiple | 0.7 | 1.0 | 33.1% |
| Shares Outstanding (Mil) | 46 | 46 | -0.2% |
| Cumulative Contribution | 34.2% |
Market Drivers
10/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| AVNS | 34.1% | |
| Market (SPY) | -0.0% | 27.7% |
| Sector (XLV) | 9.3% | 43.4% |
Fundamental Drivers
The 33.5% change in AVNS stock from 7/31/2025 to 2/15/2026 was primarily driven by a 32.3% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.17 | 14.91 | 33.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 689 | 700 | 1.6% |
| P/S Multiple | 0.7 | 1.0 | 32.3% |
| Shares Outstanding (Mil) | 46 | 46 | -0.6% |
| Cumulative Contribution | 33.5% |
Market Drivers
7/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| AVNS | 33.4% | |
| Market (SPY) | 8.2% | 35.7% |
| Sector (XLV) | 21.4% | 35.3% |
Fundamental Drivers
The -13.4% change in AVNS stock from 1/31/2025 to 2/15/2026 was primarily driven by a -15.0% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 17.22 | 14.91 | -13.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 682 | 700 | 2.7% |
| P/S Multiple | 1.2 | 1.0 | -15.0% |
| Shares Outstanding (Mil) | 46 | 46 | -0.9% |
| Cumulative Contribution | -13.4% |
Market Drivers
1/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| AVNS | -13.5% | |
| Market (SPY) | 14.3% | 41.8% |
| Sector (XLV) | 8.8% | 45.9% |
Fundamental Drivers
The -51.3% change in AVNS stock from 1/31/2023 to 2/15/2026 was primarily driven by a -60.1% change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 30.64 | 14.91 | -51.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 576 | 700 | 21.4% |
| P/S Multiple | 2.5 | 1.0 | -60.1% |
| Shares Outstanding (Mil) | 47 | 46 | 0.4% |
| Cumulative Contribution | -51.3% |
Market Drivers
1/31/2023 to 2/15/2026| Return | Correlation | |
|---|---|---|
| AVNS | -51.4% | |
| Market (SPY) | 74.0% | 36.4% |
| Sector (XLV) | 23.7% | 37.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AVNS Return | -24% | -22% | -17% | -29% | -29% | 31% | -68% |
| Peers Return | 10% | 2% | 19% | 20% | 24% | -4% | 91% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| AVNS Win Rate | 33% | 42% | 42% | 50% | 33% | 100% | |
| Peers Win Rate | 50% | 52% | 55% | 60% | 60% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| AVNS Max Drawdown | -36% | -43% | -35% | -31% | -38% | -0% | |
| Peers Max Drawdown | -8% | -21% | -7% | -4% | -1% | -8% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, BSX, ABT, CAH, SYK.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/13/2026 (YTD)
How Low Can It Go
| Event | AVNS | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -67.0% | -25.4% |
| % Gain to Breakeven | 202.7% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -40.0% | -33.9% |
| % Gain to Breakeven | 66.7% | 51.3% |
| Time to Breakeven | 197 days | 148 days |
| 2018 Correction | ||
| % Loss | -56.1% | -19.8% |
| % Gain to Breakeven | 127.8% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -50.6% | -56.8% |
| % Gain to Breakeven | 102.5% | 131.3% |
| Time to Breakeven | 766 days | 1,480 days |
Compare to MDT, BSX, ABT, CAH, SYK
In The Past
Avanos Medical's stock fell -67.0% during the 2022 Inflation Shock from a high on 2/17/2021. A -67.0% loss requires a 202.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Avanos Medical (AVNS)
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
AI Analysis | Feedback
Here are 1-3 brief analogies for Avanos Medical (AVNS):
- Imagine a Medtronic, but singularly focused on essential devices for hospital pain management, respiratory support, and digestive health.
- A Teleflex, but with its product lines exclusively dedicated to devices for pain management, respiratory health, and digestive care in clinical settings.
AI Analysis | Feedback
- Pain Management Solutions: Offers non-opioid pain relief systems, including radiofrequency ablation for chronic pain and elastomeric pumps for post-surgical pain management.
- Enteral Feeding Systems: Provides a range of devices and accessories, such as gastrostomy and nasoenteric feeding tubes, for patients requiring nutritional support.
- Respiratory Health Products: Manufactures closed suction systems and other devices designed to protect ventilated patients from ventilator-associated pneumonia.
AI Analysis | Feedback
Avanos Medical (AVNS) Major Customers
Avanos Medical (AVNS) primarily sells its medical devices and solutions to other companies within the healthcare sector, operating predominantly under a business-to-business (B2B) model. Their customers include major healthcare distributors and a wide range of healthcare providers. Avanos Medical's SEC filings (e.g., their most recent 10-K) indicate that a significant portion of their net sales is concentrated with a limited number of customers, with their largest customer accounting for approximately 11% of net sales in 2023 and their second largest accounting for approximately 10% in 2022. While Avanos does not publicly name these specific major customers, it is widely understood in the medical device industry that these are typically large medical product distributors. Based on the industry standard and common sales channels for medical device companies, Avanos's major customer base primarily includes:- Medical Distributors: These companies purchase products from manufacturers like Avanos and then distribute them to healthcare providers. Major players in this space are likely to be among Avanos's top customers. Examples of such major medical distributors include:
- Cardinal Health, Inc. (Symbol: CAH)
- McKesson Corporation (Symbol: MCK)
- Owens & Minor, Inc. (Symbol: OMI)
- Healthcare Providers: Avanos also sells directly to various healthcare facilities, which are the ultimate end-users of their products. These include:
- Hospitals (Acute Care Facilities)
- Ambulatory Surgery Centers (ASCs)
- Long-Term Care Facilities
- Home Health Agencies
AI Analysis | Feedback
null
AI Analysis | Feedback
David Pacitti
Chief Executive Officer
David Pacitti was appointed CEO of Avanos Medical, effective April 14, 2025. He brings over 30 years of professional leadership in the healthcare industry. Prior to joining Avanos, he served as president of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers, where he led marketing, sales, service, and support functions in North America and Latin America across the Siemens Healthineers portfolio. Before Siemens Healthineers, which he joined in 2015, Mr. Pacitti held several leadership roles at Abbott Vascular, including division vice president of U.S. commercial operations, sales and marketing, vice president of commercial operations (2009-2013), and vice president of global marketing (2006-2009). He joined Abbott Vascular through its acquisition of Guidant Corp, where he held positions of increasing responsibility from 1995 to 2006. Mr. Pacitti serves as chair of the AdvaMed Medical Imaging Technology Division's board of directors and on the boards for Orchestra BioMed and the Siemens Foundation.
Scott Galovan
Senior Vice President and Chief Financial Officer
Scott Galovan was appointed Senior Vice President and Chief Financial Officer of Avanos Medical, effective August 1, 2025. He previously served as Avanos' Senior Vice President of Strategy and Corporate Development. With 12 years of experience at Avanos, Mr. Galovan has a proven track record of leading acquisition and divestiture initiatives, including the sale of the Surgical & Infection Prevention business to Owens & Minor and the Respiratory Health business to AirLife, as well as acquisitions such as CORPAK, Game Ready, Summit Medical, NeoMed, OrthogenRx, and Diros Medical. Before joining Avanos, he spent 10 years in various strategy, finance, and M&A roles for Newell Brands, Equity Pacific Partners, and Intel Capital. His role as a Principal at Equity Pacific Partners indicates experience with private equity-backed organizations.
Kerr Holbrook
Senior Vice President and Chief Commercial Officer
Kerr Holbrook was named Senior Vice President and Chief Commercial Officer in January 2023. He joined Avanos in 2019 as Senior Vice President and General Manager for the company’s Chronic Care franchise. Mr. Holbrook has over 25 years of experience as a healthcare industry executive, focusing on sales, marketing, strategy, and general management. Prior to Avanos, he served as chief commercial officer at AlloSource, a global biologic and regenerative implant company.
Camille Chang Gilmore
Senior Vice President and Chief Human Resources Officer
Camille Chang Gilmore leads Avanos Medical’s global people strategy, overseeing talent acquisition, workforce planning, leadership development, and the overall employee experience.
Moji James
Senior Vice President and General Counsel
Moji James serves as the Senior Vice President and General Counsel for Avanos Medical.
AI Analysis | Feedback
The key risks to Avanos Medical (AVNS) include persistent losses and a lack of revenue and earnings growth, the impact of tariffs and inflationary pressures, and risks associated with public healthcare policy and reimbursement levels.
- Persistent Losses and Lack of Revenue and Earnings Growth: Avanos Medical has faced significant challenges with profitability, reporting widening losses at an average rate of 74.4% per year over the past five years. The company's net profit margin shows no signs of improvement, and neither revenue nor earnings are expected to show meaningful growth in the near term. This sustained lack of profitability and growth erodes the case for a near-term fundamental re-rating and underscores persistent execution hurdles.
- Impact of Tariffs and Inflationary Pressures: Tariffs are identified as a major headwind for Avanos Medical, pressuring margins and contributing to lowered adjusted earnings per share (EPS) guidance. The company's profitability has been directly affected, with a swing to a net loss in Q3 2025 partly due to tariff impacts. Additionally, inflationary pressures pose a general risk to the business.
- Public Healthcare Policy and Reimbursement Levels: Changes in public healthcare policy, such as potential Medicare and Medicaid cuts to hospitals and healthcare providers, could negatively impact demand and pricing power for Avanos products. Broader legislative and regulatory actions, including changes in governmental regulations and reimbursement levels from third-party payors, are also identified as risks that could materially affect the company's business, financial position, results of operations, or cash flows.
AI Analysis | Feedback
null
AI Analysis | Feedback
Avanos Medical (AVNS) operates primarily in two main product areas: Pain Management & Recovery and Specialty Nutrition Systems.
Pain Management & Recovery
The global market for pain management devices, which includes solutions offered by Avanos Medical such as non-opioid pain therapies, radiofrequency ablation (RFA), and infusion pumps, is substantial and growing.
- The global pain management devices market size was estimated at approximately USD 7.94 billion in 2024.
- This market is projected to grow to USD 9.3 billion by 2032, with a compound annual growth rate (CAGR) of approximately 8% from 2025 to 2032.
- Another estimate projects the global market to reach USD 13.32 billion by 2035, growing at a CAGR of 4.7% during the forecast period.
- North America held the largest share of this market, accounting for 48% in 2022.
Specialty Nutrition Systems (Enteral Feeding Devices)
Avanos Medical's Specialty Nutrition Systems segment includes enteral feeding devices and solutions.
- The global enteral feeding devices market size was USD 3.52 billion in 2021.
- This market is expected to grow at a CAGR of 6.6% over the projection period.
AI Analysis | Feedback
Avanos Medical (AVNS) is anticipated to drive future revenue growth over the next two to three years through several key strategies:
- Growth in Specialty Nutrition Systems (SNS) Segment: The company expects continued strong performance from its Specialty Nutrition Systems segment, which has demonstrated double-digit expansion, particularly in enteral feeding and neonatal solutions. New product adoption within platforms such as CORTRAK and CORGRIP is reinforcing Avanos' leadership and capturing market share.
- Expansion in Pain Management and Recovery (PM&R) Segment, particularly Radiofrequency Ablation (RFA): The Pain Management and Recovery segment has shown a return to growth, primarily fueled by sustained momentum in Radiofrequency Ablation (RFA) product sales.
- Strategic Acquisitions: Avanos is pursuing strategic acquisitions to enhance its product offerings and market presence. The recent acquisition of Nexus Medical is expected to immediately boost revenue growth by expanding its footprint in neonatal and pediatric critical care settings. The company also continues to explore additional merger and acquisition opportunities that align with its core Digestive Health and Pain Management & Recovery franchises.
- New Product Launches and Innovation: Product innovation is a key focus, with new launches such as the CORGRIP SR Nasogastric/Nasointestinal Tube Retention System expanding the comprehensive Enteral Feeding portfolio. Avanos has a three-year plan that prioritizes product innovation to drive growth.
- Commercial and Portfolio Optimization: The company is undergoing a three-year transformation plan designed to optimize its commercial operations and streamline its portfolio. This includes divesting non-core assets and focusing on consistent growth and portfolio expansion within its strategic Digestive Health and Pain Management & Recovery franchises, which is aimed at enhancing overall revenue generation.
AI Analysis | Feedback
Share Repurchases
- In December 2021, Avanos Medical's Board of Directors authorized a share repurchase program for up to $30 million of the company's common stock.
- A new stock repurchase program was approved by the Board in November 2024, allowing the company to buy back up to $25 million of its common stock over the subsequent year.
- For the nine months ended September 30, 2025, Avanos Medical withheld $3.0 million in common shares for taxes related to stock-based compensation, in addition to its ongoing share repurchase program.
Outbound Investments
- In December 2021, Avanos Medical announced the acquisition of OrthogenRx, Inc. for $160 million, consisting of $130 million in cash at closing and up to $30 million in contingent cash consideration, enhancing its interventional pain portfolio.
- Avanos Medical acquired Nexus Medical, LLC in September 2025, adding the proprietary TKO® anti-reflux needleless connector technology to its Specialty Nutrition Systems business, a move expected to be immediately accretive to revenue and earnings per share.
- The company made strategic portfolio adjustments, including the divestiture of its HA product line to Channel-Markers Medical, LLC in July 2025 and the agreement to sell its U.S. Game Ready® Orthopedic Rental Business to WRS Group in October 2025.
Capital Expenditures
- For the nine months ended September 30, 2025, capital expenditures totaled $24.7 million, an increase from $13.0 million in the comparable prior year period.
- In the first quarter of 2025, capital expenditures were $6.7 million.
- Avanos expects slightly higher capital expenditures in 2025 due to prioritized supply chain investments aimed at accelerating its exit from China for neonatal syringe production by mid-2026.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 106.14 |
| Mkt Cap | 119.0 |
| Rev LTM | 29,937 |
| Op Inc LTM | 4,390 |
| FCF LTM | 4,744 |
| FCF 3Y Avg | 3,221 |
| CFO LTM | 5,572 |
| CFO 3Y Avg | 3,840 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.2% |
| Rev Chg 3Y Avg | 7.6% |
| Rev Chg Q | 9.2% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Mgn LTM | 18.4% |
| Op Mgn 3Y Avg | 17.1% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 20.3% |
| CFO/Rev 3Y Avg | 19.2% |
| FCF/Rev LTM | 15.4% |
| FCF/Rev 3Y Avg | 14.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 119.0 |
| P/S | 4.1 |
| P/EBIT | 21.3 |
| P/E | 28.9 |
| P/CFO | 19.7 |
| Total Yield | 3.7% |
| Dividend Yield | 0.9% |
| FCF Yield 3Y Avg | 3.7% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 1.6% |
| 3M Rtn | 3.0% |
| 6M Rtn | 2.5% |
| 12M Rtn | -7.1% |
| 3Y Rtn | 36.8% |
| 1M Excs Rtn | 2.7% |
| 3M Excs Rtn | 2.5% |
| 6M Excs Rtn | -2.1% |
| 12M Excs Rtn | -19.8% |
| 3Y Excs Rtn | -32.1% |
Price Behavior
Price Behavior
| Market Price | $14.90 | |
| Market Cap ($ Bil) | 0.7 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -10.1% | |
| 50 Days | 200 Days | |
| DMA Price | $12.40 | $11.98 |
| DMA Trend | indeterminate | up |
| Distance from DMA | 20.2% | 24.4% |
| 3M | 1YR | |
| Volatility | 35.7% | 38.1% |
| Downside Capture | -22.84 | 90.41 |
| Upside Capture | 132.16 | 68.07 |
| Correlation (SPY) | 37.7% | 41.3% |
AVNS Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.80 | 0.67 | 0.72 | 1.23 | 0.82 | 0.90 |
| Up Beta | 4.24 | 3.68 | 2.82 | 2.68 | 0.77 | 0.82 |
| Down Beta | -0.02 | 0.14 | -0.01 | 0.79 | 0.76 | 0.62 |
| Up Capture | 244% | 114% | 108% | 115% | 60% | 59% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 12 | 21 | 31 | 62 | 115 | 359 |
| Down Capture | -141% | -42% | 1% | 88% | 109% | 108% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 7 | 19 | 29 | 60 | 130 | 380 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AVNS | |
|---|---|---|---|---|
| AVNS | -5.4% | 38.2% | -0.06 | - |
| Sector ETF (XLV) | 9.6% | 17.4% | 0.37 | 46.3% |
| Equity (SPY) | 14.0% | 19.4% | 0.55 | 41.3% |
| Gold (GLD) | 74.3% | 25.3% | 2.17 | 4.3% |
| Commodities (DBC) | 7.0% | 16.7% | 0.24 | 12.1% |
| Real Estate (VNQ) | 7.9% | 16.6% | 0.28 | 45.9% |
| Bitcoin (BTCUSD) | -29.8% | 44.9% | -0.65 | 16.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AVNS | |
|---|---|---|---|---|
| AVNS | -20.6% | 37.1% | -0.52 | - |
| Sector ETF (XLV) | 8.0% | 14.5% | 0.37 | 40.9% |
| Equity (SPY) | 13.3% | 17.0% | 0.62 | 41.4% |
| Gold (GLD) | 22.1% | 17.0% | 1.06 | 7.2% |
| Commodities (DBC) | 10.5% | 18.9% | 0.44 | 9.2% |
| Real Estate (VNQ) | 5.2% | 18.8% | 0.18 | 43.8% |
| Bitcoin (BTCUSD) | 8.3% | 57.2% | 0.37 | 15.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AVNS | |
|---|---|---|---|---|
| AVNS | -4.8% | 39.3% | 0.00 | - |
| Sector ETF (XLV) | 11.2% | 16.5% | 0.56 | 48.1% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 48.7% |
| Gold (GLD) | 15.3% | 15.6% | 0.82 | 3.1% |
| Commodities (DBC) | 8.1% | 17.6% | 0.38 | 17.0% |
| Real Estate (VNQ) | 6.4% | 20.7% | 0.27 | 45.4% |
| Bitcoin (BTCUSD) | 67.9% | 66.7% | 1.07 | 11.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/5/2025 | -5.7% | 3.2% | -0.4% |
| 8/5/2025 | -12.1% | -6.5% | 9.8% |
| 2/26/2025 | 0.4% | -3.5% | -9.0% |
| 10/30/2024 | -17.9% | -12.6% | -15.4% |
| 7/31/2024 | 4.2% | -0.1% | 5.0% |
| 5/2/2024 | 4.9% | 4.1% | 6.0% |
| 2/20/2024 | 1.6% | 0.4% | 1.3% |
| 11/1/2023 | 13.2% | 15.5% | 17.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 11 | 9 |
| # Negative | 9 | 12 | 14 |
| Median Positive | 4.3% | 6.7% | 9.6% |
| Median Negative | -5.7% | -10.1% | -11.0% |
| Max Positive | 13.2% | 18.4% | 20.9% |
| Max Negative | -17.9% | -20.5% | -24.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/21/2024 | 10-K |
| 09/30/2023 | 11/01/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/21/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/04/2022 | 10-Q |
| 12/31/2021 | 02/23/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Holbrook, Kerr | SVP, Chief Commercial Officer | Direct | Sell | 11192025 | 11.00 | 15,000 | 165,014 | 922,539 | Form |
| 2 | Blackford, Gary | Direct | Buy | 8152025 | 10.97 | 20,000 | 219,500 | 1,005,233 | Form | |
| 3 | Blackford, Gary | Shares held in trust. | Buy | 8152025 | 10.99 | 40,000 | 439,800 | 439,800 | Form | |
| 4 | Holbrook, Kerr | SVP, Chief Commercial Officer | Direct | Sell | 3102025 | 15.25 | 7,000 | 106,778 | 1,251,545 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.